Review



polyclonal rabbit anti human cxcr3 antibody  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology polyclonal rabbit anti human cxcr3 antibody
    CXCL10 and <t>CXCR3</t> membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.
    Polyclonal Rabbit Anti Human Cxcr3 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 72 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+anti+human+cxcr3+antibody/IP-10+Antibody/pmc04726926-112-21-12
    Average 93 stars, based on 72 article reviews
    polyclonal rabbit anti human cxcr3 antibody - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer"

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    Journal: Molecular and Clinical Oncology

    doi: 10.3892/mco.2015.665

    CXCL10 and CXCR3 membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.
    Figure Legend Snippet: CXCL10 and CXCR3 membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.

    Techniques Used: Staining, Expressing

    Immunostaining for CXCL10 and CXCR3 expression in normal and CRC tissues.
    Figure Legend Snippet: Immunostaining for CXCL10 and CXCR3 expression in normal and CRC tissues.

    Techniques Used: Immunostaining, Expressing

    Immunostaining for CXCL10 and CXCR3 in colorectal cancer (negative expression samples are absent).
    Figure Legend Snippet: Immunostaining for CXCL10 and CXCR3 in colorectal cancer (negative expression samples are absent).

    Techniques Used: Immunostaining, Expressing

    Survival curve of CXCR3 expression. (A) Patients with strong expression (n=14) exhibited significantly shorter disease-free survival (DFS) compared with those with low expression (n=69, P<0.0001, log-rank test) and negative expression (n=60, P<0.0001, log-rank test); low vs. negative expression, P=0.012. (B) Patients with strong expression also exhibited significantly shorter overall survival (OS) compared with those with low expression (P<0.0001) and negative expression (P<0.0001); however, there was no significant difference between low and negative expression (P=0.184).
    Figure Legend Snippet: Survival curve of CXCR3 expression. (A) Patients with strong expression (n=14) exhibited significantly shorter disease-free survival (DFS) compared with those with low expression (n=69, P<0.0001, log-rank test) and negative expression (n=60, P<0.0001, log-rank test); low vs. negative expression, P=0.012. (B) Patients with strong expression also exhibited significantly shorter overall survival (OS) compared with those with low expression (P<0.0001) and negative expression (P<0.0001); however, there was no significant difference between low and negative expression (P=0.184).

    Techniques Used: Expressing

    Association between CXCL10/CXCR3 and prognosis
    Figure Legend Snippet: Association between CXCL10/CXCR3 and prognosis

    Techniques Used: Expressing

    Kaplan-Meier analysis of cancer-specific overall survival (OS) of relapsed patients with stage II colorectal cancer subdivided by the presence of inflammatory adhesions and CXCR3 expression (P<0.0001). Expression of CXCR3 (A) in cases without adhesions and (B) in cases with adhesions.
    Figure Legend Snippet: Kaplan-Meier analysis of cancer-specific overall survival (OS) of relapsed patients with stage II colorectal cancer subdivided by the presence of inflammatory adhesions and CXCR3 expression (P<0.0001). Expression of CXCR3 (A) in cases without adhesions and (B) in cases with adhesions.

    Techniques Used: Expressing

    Related Articles

    Blocking Assay:

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer
    Article Snippet: .. A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking. .. Immunoperoxidase staining was performed with the two-step EnVisionTM method (DakoCytomation, Glostrup, Denmark) according to the manufacturer's instructions and visualized with 3,3′-diaminobenzidine (Sigma, St. Louis, MO, USA).



    Similar Products

    polyclonal rabbit anti-human cxcr3 antibody  (Thermo Fisher)
    90
    Thermo Fisher polyclonal rabbit anti-human cxcr3 antibody
    Polyclonal Rabbit Anti Human Cxcr3 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+anti+human+cxcr3+antibody/cxcr4+antibody/pm24154640-49-2-10
    Average 90 stars, based on 1 article reviews
    polyclonal rabbit anti-human cxcr3 antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rabbit anti human cxcr3 polyclonal  (Abcam)
    99
    Abcam rabbit anti human cxcr3 polyclonal
    HRP2 induces inflammatory cytokines (CXCL10, Ang2/Ang1 ratio) in cortical organoids Representative cortical organoids at 50 days in culture treated with HRP2 and NRG1 and stained for CXCL10 (A), its <t>receptor</t> <t>CXCR3</t> (C), Angiopoietin 1 (E), and Angiopoietin 2 (G). Quantification of CXCL10 (B), CXCR3 (D), Ang1 (F), and Ang2 (H) shows that HRP2 significantly induces inflammation. CXCL10, CXCR3, and Ang2 are increased by HRP2, whereas NRG1 reversed this effect. Data are represented as means ± SEM of N = 3 biological replicates; a: p < 0.05 compared to basal conditions; b: p < 0.05 compared to HRP2 treatment. One-way ANOVA and t -test were used. Scale bar: 20 μm.
    Rabbit Anti Human Cxcr3 Polyclonal, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+anti+human+cxcr3+antibody/Nitrocellulose+Transfer+Membrane-+-+10Membrane/pmc09157207-20-0-5
    Average 99 stars, based on 1 article reviews
    rabbit anti human cxcr3 polyclonal - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    rabbit anti human cxcr3 polyclonal antibody  (Boster Bio)
    91
    Boster Bio rabbit anti human cxcr3 polyclonal antibody
    HRP2 induces inflammatory cytokines (CXCL10, Ang2/Ang1 ratio) in cortical organoids Representative cortical organoids at 50 days in culture treated with HRP2 and NRG1 and stained for CXCL10 (A), its <t>receptor</t> <t>CXCR3</t> (C), Angiopoietin 1 (E), and Angiopoietin 2 (G). Quantification of CXCL10 (B), CXCR3 (D), Ang1 (F), and Ang2 (H) shows that HRP2 significantly induces inflammation. CXCL10, CXCR3, and Ang2 are increased by HRP2, whereas NRG1 reversed this effect. Data are represented as means ± SEM of N = 3 biological replicates; a: p < 0.05 compared to basal conditions; b: p < 0.05 compared to HRP2 treatment. One-way ANOVA and t -test were used. Scale bar: 20 μm.
    Rabbit Anti Human Cxcr3 Polyclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+anti+human+cxcr3+antibody/Anti-CXCR3+Antibody/pm26434630-42-7-18
    Average 91 stars, based on 1 article reviews
    rabbit anti human cxcr3 polyclonal antibody - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    polyclonal rabbit anti human cxcr3 antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology polyclonal rabbit anti human cxcr3 antibody
    CXCL10 and <t>CXCR3</t> membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.
    Polyclonal Rabbit Anti Human Cxcr3 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+anti+human+cxcr3+antibody/IP-10+Antibody/pmc04726926-112-21-12
    Average 93 stars, based on 1 article reviews
    polyclonal rabbit anti human cxcr3 antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    primary rabbit anti human cxcr3 polyclonal antibody  (Boster Bio)
    91
    Boster Bio primary rabbit anti human cxcr3 polyclonal antibody
    CXCL10 and <t>CXCR3</t> membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.
    Primary Rabbit Anti Human Cxcr3 Polyclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+anti+human+cxcr3+antibody/Anti-CXCR3+Antibody/10__1038_slash_modpathol__2015__15-4095-40-47
    Average 91 stars, based on 1 article reviews
    primary rabbit anti human cxcr3 polyclonal antibody - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    primary rabbit anti-human cxcr3 polyclonal antibody  (Boster Bio)
    90
    Boster Bio primary rabbit anti-human cxcr3 polyclonal antibody
    CXCL10 and <t>CXCR3</t> membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.
    Primary Rabbit Anti Human Cxcr3 Polyclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+anti+human+cxcr3+antibody/Anti-GIPR+Antibody/10__1038_slash_labinvest__2015__11-4095-40-47
    Average 90 stars, based on 1 article reviews
    primary rabbit anti-human cxcr3 polyclonal antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    HRP2 induces inflammatory cytokines (CXCL10, Ang2/Ang1 ratio) in cortical organoids Representative cortical organoids at 50 days in culture treated with HRP2 and NRG1 and stained for CXCL10 (A), its receptor CXCR3 (C), Angiopoietin 1 (E), and Angiopoietin 2 (G). Quantification of CXCL10 (B), CXCR3 (D), Ang1 (F), and Ang2 (H) shows that HRP2 significantly induces inflammation. CXCL10, CXCR3, and Ang2 are increased by HRP2, whereas NRG1 reversed this effect. Data are represented as means ± SEM of N = 3 biological replicates; a: p < 0.05 compared to basal conditions; b: p < 0.05 compared to HRP2 treatment. One-way ANOVA and t -test were used. Scale bar: 20 μm.

    Journal: iScience

    Article Title: Neuregulin-1/ErbB4 signaling modulates Plasmodium falciparum HRP2-induced damage to brain cortical organoids

    doi: 10.1016/j.isci.2022.104407

    Figure Lengend Snippet: HRP2 induces inflammatory cytokines (CXCL10, Ang2/Ang1 ratio) in cortical organoids Representative cortical organoids at 50 days in culture treated with HRP2 and NRG1 and stained for CXCL10 (A), its receptor CXCR3 (C), Angiopoietin 1 (E), and Angiopoietin 2 (G). Quantification of CXCL10 (B), CXCR3 (D), Ang1 (F), and Ang2 (H) shows that HRP2 significantly induces inflammation. CXCL10, CXCR3, and Ang2 are increased by HRP2, whereas NRG1 reversed this effect. Data are represented as means ± SEM of N = 3 biological replicates; a: p < 0.05 compared to basal conditions; b: p < 0.05 compared to HRP2 treatment. One-way ANOVA and t -test were used. Scale bar: 20 μm.

    Article Snippet: Rabbit anti-Human CXCR3 Polyclonal , Abcam , Cat #ab133420 RRID: AB_11154962.

    Techniques: Staining

    Journal: iScience

    Article Title: Neuregulin-1/ErbB4 signaling modulates Plasmodium falciparum HRP2-induced damage to brain cortical organoids

    doi: 10.1016/j.isci.2022.104407

    Figure Lengend Snippet:

    Article Snippet: Rabbit anti-Human CXCR3 Polyclonal , Abcam , Cat #ab133420 RRID: AB_11154962.

    Techniques: Functional Assay, Recombinant, Plasmid Preparation, CCK-8 Assay, Bicinchoninic Acid Protein Assay, Isolation, Expressing, Western Blot, Software, Microscopy

    CXCL10 and CXCR3 membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: CXCL10 and CXCR3 membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Staining, Expressing

    Immunostaining for CXCL10 and CXCR3 expression in normal and CRC tissues.

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Immunostaining for CXCL10 and CXCR3 expression in normal and CRC tissues.

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Immunostaining, Expressing

    Immunostaining for CXCL10 and CXCR3 in colorectal cancer (negative expression samples are absent).

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Immunostaining for CXCL10 and CXCR3 in colorectal cancer (negative expression samples are absent).

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Immunostaining, Expressing

    Survival curve of CXCR3 expression. (A) Patients with strong expression (n=14) exhibited significantly shorter disease-free survival (DFS) compared with those with low expression (n=69, P<0.0001, log-rank test) and negative expression (n=60, P<0.0001, log-rank test); low vs. negative expression, P=0.012. (B) Patients with strong expression also exhibited significantly shorter overall survival (OS) compared with those with low expression (P<0.0001) and negative expression (P<0.0001); however, there was no significant difference between low and negative expression (P=0.184).

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Survival curve of CXCR3 expression. (A) Patients with strong expression (n=14) exhibited significantly shorter disease-free survival (DFS) compared with those with low expression (n=69, P<0.0001, log-rank test) and negative expression (n=60, P<0.0001, log-rank test); low vs. negative expression, P=0.012. (B) Patients with strong expression also exhibited significantly shorter overall survival (OS) compared with those with low expression (P<0.0001) and negative expression (P<0.0001); however, there was no significant difference between low and negative expression (P=0.184).

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Expressing

    Association between CXCL10/CXCR3 and prognosis

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Association between CXCL10/CXCR3 and prognosis

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Expressing

    Kaplan-Meier analysis of cancer-specific overall survival (OS) of relapsed patients with stage II colorectal cancer subdivided by the presence of inflammatory adhesions and CXCR3 expression (P<0.0001). Expression of CXCR3 (A) in cases without adhesions and (B) in cases with adhesions.

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Kaplan-Meier analysis of cancer-specific overall survival (OS) of relapsed patients with stage II colorectal cancer subdivided by the presence of inflammatory adhesions and CXCR3 expression (P<0.0001). Expression of CXCR3 (A) in cases without adhesions and (B) in cases with adhesions.

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Expressing